A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children With Refractory or Recurrent Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs SGT 53 (Primary) ; Cyclophosphamide; Topotecan
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors SynerGene Therapeutics
- 15 May 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 15 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 04 Nov 2015 New trial record